0 CHECKOUT

Antibodies in Oncology Drug Pipeline Update

  • ID: 1197080
  • August 2016
  • Region: Global
  • Bioseeker
1 of 2

The commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second wave in the lucrative field of therapeutic antibodies.

There are today 542 companies plus partners developing 1308 antibody drugs in 3051 developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 407 drugs. Antibodies In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 414 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 390 out of the 394 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 61 classifications of molecular function and with pathway referrals to READ MORE >

Note: Product cover images may vary from those shown
2 of 2
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Photocure ASA
  • Roche Diagnostics Ltd.
  • Abbott Laboratories Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Becton, Dickinson and Company (BD)